Albireo Pharma (ALBO) 10-K 19 Dec 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Nov. 28, 2014	Mar. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Biodel Inc
Entity Central Index Key	1322505
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Document Type	10-K
Document Period End Date	30-Sep-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$58
Entity Common Stock, Shares Outstanding		23,445,600

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Current:
Cash and cash equivalents	$24,588	$39,781
Taxes receivable	5	6
Grant receivable		26
Prepaid and other assets	311	264
Total current assets	24,904	40,077
Property and equipment, net	481	1,031
Intellectual property, net	40	43
Total assets	25,425	41,151
Current:
Accounts payable	172	246
Accrued expenses:
Clinical trial expenses	214	181
Payroll and related	958	1,139
Accounting and legal fees	131	226
Severance		255
Other	141	319
Income taxes payable		75
Total current liabilities	1,616	2,441
Common stock warrant liability	1,014	6,121
Severance payable, long term portion		26
Total liabilities	2,630	8,588
Commitments
Stockholders' equity:
Convertible preferred stock, $.01 par value; 50,000,000 shares authorized, 1,950,000 and 1,950,000 issued and outstanding	19	19
Common stock, $.01 par value; 62,500,000 shares authorized; 21,070,824 and 23,079,543 issued and outstanding, respectively	231	211
Additional paid-in capital	252,104	247,761
Accumulated deficit	-229,559	-215,428
Total stockholders' equity	22,795	32,563
Total liabilities and stockholders' equity	$25,425	$41,151

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Balance Sheets [Abstract]
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	1,950,000	1,950,000
Preferred stock, shares outstanding	1,950,000	1,950,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	62,500,000	62,500,000
Common stock, shares issued	23,079,543	21,070,824
Common stock, shares outstanding	23,079,543	21,070,824

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
Revenue
Operating expenses:
Research and development	14,194	14,296
Government grants	-531	-546
General and administrative	5,598	6,843
Total operating expenses	19,261	20,593
Other (income):
Interest and other income	-49	-56
Adjustments to fair value of common stock warrant liability	-5,107	-1,217
Loss before tax provision	-14,105	-19,320
Tax provision	26	15
Net loss	($14,131)	($19,335)
Net loss per share - basic and diluted	($0.66)	($1.24)
Weighted average shares outstanding - basic and diluted	21,404,258	15,650,538

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock $.01 Par Value	Series A Preferred stock $.01 Par Value	Series B Preferred stock $.01 Par Value	Additional Paid in Capital	Accumulated Deficit
In Thousands, except Share data
Balance at Sep. 30, 2012	$31,016	$142	$18	$36	$226,913	($196,093)
Balance (in shares) at Sep. 30, 2012		14,174,545	1,813,944	3,605,607
Proceeds from sale of common stock	19,239	47			19,192
Proceeds from sale of common stock, shares		4,718,767
Preferred stock conversion		22	-18	-17	13
Preferred stock conversion, shares		2,109,090	-1,813,944	-1,655,607
Stock-based compensation	1,538				1,538
Proceeds from the sale of stock-ESPP	30				30
Proceeds from the sale of stock-ESPP (in shares)		13,395
Stock options exercised	75				75
Stock options exercised (in shares)		30,250
RSUs granted		24,777
Net loss	-19,335					-19,335
Balance at Sep. 30, 2013	32,563	211		19	247,761	-215,428
Balance (in shares) at Sep. 30, 2013		21,070,824		1,950,000
Proceeds from ATM facility	3,026	16			3,010
Proceeds from ATM facility,shares		1,564,821
Proceeds from equity line	490	4			486
Proceeds from equity line, shares		395,000
Stock-based compensation	784				784
Proceeds from the sale of stock-ESPP	15				15
Proceeds from the sale of stock-ESPP (in shares)		8,189
Stock options exercised	48				48
Stock options exercised (in shares)		19,241
RSUs converted to common stock
RSUs converted to common stock (in shares)		21,468
Net loss	-14,131					-14,131
Balance at Sep. 30, 2014	$22,795	$231		$19	$252,104	($229,559)
Balance (in shares) at Sep. 30, 2014		23,079,543		1,950,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net loss	($14,131)	($19,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	603	641
Stock-based compensation for employees and directors	784	1,538
Adjustments to fair value of common stock warrant liability	-5,107	-1,217
(Increase) decrease in:
Prepaid expenses and other assets	-47	31
Income taxes receivable	1	28
Grant receivable	26	63
Other receivable		8
Increase (decrease) in:
Accounts payable	-74	-39
Income tax payable	-75	-26
Accrued expenses and other liabilities	-703	-247
Total adjustments	-4,592	780
Net cash used in operating activities	-18,723	-18,555
Cash flows from investing activities:
Purchase of property and equipment	-49	-118
Net cash used in investing activities	-49	-118
Cash flows from financing activities:
Restricted cash		60
Options exercised	48	75
Net proceeds from employee stock purchase plan	15	30
Net proceeds from ATM facility	3,026
Net proceeds from equity line	490
Net proceeds from sale of common stock		19,239
Net cash provided by financing activities	3,579	19,404
Net increase (decrease) in cash and cash equivalents	-15,193	731
Cash and cash equivalents, beginning of period	39,781	39,050
Cash and cash equivalents, end of period	24,588	39,781
Cash paid for interest and income taxes:
Interest
Income taxes	25	12
Non-cash financing and investing activities
Conversion of convertible preferred stock to common stock		$35

Business

Business	12 Months Ended
	Sep. 30, 2014
Business [Abstract]
Business	1. Business
	Business
	Biodel Inc. and its wholly owned subsidiary (collectively, "Biodel" or the "Company", and formerly Global Positioning Group Ltd.) is a specialty pharmaceutical company located in Danbury, Connecticut. The Company was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. The Company formed a wholly owned subsidiary in the United Kingdom in October 2011 ("Biodel UK Limited"). This subsidiary has been inactive since its inception.

Basis_of_Presentation_and_Goin

Basis of Presentation and Going Concern	12 Months Ended
	Sep. 30, 2014
Basis of Presentation and Going Concern [Abstract]
Basis of Presentation and Going Concern	2. Basis of Presentation and Going Concern
	In June 2014, the FASB issued ASU No. 2014-10, to eliminate the concept of a development stage entity (DSE) from U.S. GAAP, effective for interim periods and years beginning after December 15, 2014. The issuance of ASU No. 2014-10 rescinds certain financial reporting requirements that have historically applied to DSEs, such as inception-to-date information in the statements of income, cash flows, and stockholder equity. Additionally, the financial statements no longer need to be labeled as those of a DSE. ASU No. 2014-10 was early adopted and the adoption of this standard did not have a material effect on the Company's financial statements.
	These consolidated financial statements as of September 30, 2014 have been prepared under the assumption that the Company will continue as a going concern. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt in the Company’s ability to continue as a going concern without additional capital becoming available. While the Company could sell an additional $9.2 million worth of common stock through its Sales Agreement with MLV & Co. LLC or direct Lincoln Park Capital Fund, LLC to purchase up to $14 million worth of shares of common stock under the Company’s stock purchase agreement with Lincoln Park Capital Fund, LLC, there are certain factors, such as volume of trading in the stock, the stock price and the ability to terminate the agreement with notice, which could limit the amount the Company could raise in a short period of time (see Note 9). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company will be required to raise additional capital within the next year to continue the development and commercialization of current product candidates and to continue to fund operations at the current cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company's stockholders may experience significant dilution. If the Company is unable to raise additional capital when required or on acceptable terms, the Company may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize ourselves on unfavorable terms.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies
	Research and Development Costs
	The Company is in the business of research and development and, therefore, research and development costs include, but are not limited to, salaries and benefits, lab supplies, preclinical fees, clinical trial and related clinical manufacturing costs, allocated overhead costs and professional service providers. Research and development costs are expensed when incurred. Research and development costs aggregated $14,296, and $14,194 for the years ended September 30, 2013 and 2014, respectively.
	Government Grants
	Grants received are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The Company requests cash funding under approved grants as expenses are incurred (not in advance) and report these receipts on the statement of operations as a separate line item entitled "Government Grants". The corresponding expenses are included in research and development expenses. In July and September 2012, the Company was awarded two National Institutes of Health grants for the development of a concentrated ultra-rapid-acting insulin formulation and a stable glucagon formulation for use in an artificial pancreas, in the amounts of $582 and $583, respectively. Each award was for two years.
	Work on the grant for the development of concentrated ultra-rapid-acting insulin formulation started in August 2012 and completed in June 2014. Expenses incurred and grant income were $327 and $167, for the years ended September 30, 2013 and 2014, respectively.
	Work on the grant for the stable glucagon formulation started in January 2013 and completed in June 2014. Expenses incurred and grant income were $219 and $364 for the years ended September 30, 2013 and 2014, respectively.
	The Company reported grant income of $546 and $531, for the years ended September 30, 2013 and 2014, respectively.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions including, but not limited to, accruals, forfeiture rate used in the computation of share-based compensation, deferred tax assets, and warrant liability estimated at fair value. Actual results may differ from those estimates.
	Cash and Cash Equivalents
	The Company considers currency on hand, demand deposits and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. As of September 30, 2013 and 2014, the Company had cash and cash equivalents of $39,781 and $24,588, respectively, which are primarily held in a premium commercial money market account.
	Fair Value of Financial Instruments
	The carrying amounts of the Company's financial instruments, which include cash and cash equivalents and accounts payable, approximate their fair values due to their short term maturities. Warrant liability is recorded at fair value.
	Pre-Launch Inventory
	Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expense during the period the costs are incurred. Because all of its product candidates are in early stages of preclinical or clinical development, the Company currently expenses all purchases of pre-launch inventory as research and development, and expects to continue to do so until it can determine the probability of regulatory approval for the applicable product candidate.
	For the years ended September 30, 2013 and 2014, the Company expensed $121 and $3, respectively, of costs associated with the purchase of RHI and glucagon as research and development expense after such materials passed quality control inspection by the Company and transfer of title occurred.
	Intellectual Property
	Intangible assets consist primarily of capitalized costs associated with the Company's ultra-rapid-acting insulin patents and the purchase of two domain addresses. They are amortized using the straight-line method over twenty years. If the Company determines that a patent will not result in future revenues, the cost related to such patent will be expensed in full on the date of that determination. Intellectual property amortization expense was $3 for each of the years ended September 30, 2013 and 2014.
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation or amortization. Major improvements are capitalized, while maintenance and repairs are expensed in the period the cost is incurred. Property and equipment are depreciated over their estimated useful lives using the straight-line method. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in other income (expense) in the statement of operations. Estimated useful lives for each asset category are as follows: Furniture and fixtures — 7 years; Leasehold improvements — estimated useful life or remaining term of lease, whichever is shorter; Laboratory equipment — 7 years; Manufacturing equipment — 5 years; Device development— 5 years; Facility equipment— 3 years and 7 years; Computer equipment — 5 years; and Computer software — 3 years.
	Impairment of Long-Lived Assets
	Whenever events or changes in circumstances indicate that the carrying amounts of a long-lived asset may not be recoverable, the Company reviews these assets for impairment and determines whether adjustments are needed to carrying values. There were no adjustments to the carrying value of long-lived assets at September 30, 2013 and 2014.
	Warrant Liability
	The Company applies the provisions of Accounting Standards Codification Topic 480 ("ASC 480") (formerly FASB Staff Position 150-5 (FSP 15-5)), Issuers Accounting under FASB Statement No. 150 for Freestanding Warrants and other Similar Instruments on Shares that are Redeemable or Distinguishing Liabilities from Equities. Pursuant to ASC 480, a freestanding financial instrument (other than outstanding share) that, at inception, embodies an obligation to repurchase the issuer's shares and "requires or may require" the obligation to be settled by transferring assets, qualifies as a liability (if the obligation is conditional, the number of conditions is irrelevant).
	The Company issued warrants in May 2011 and June 2012 and recorded a liability determined by the Black-Scholes valuation model. The Black-Scholes valuation model was used because the warrants do not contain a repricing provision. The Black-Scholes valuation model takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the term of the warrant. These warrants will be revalued at each reporting period and changes in fair value are recognized currently in the statements of operations under the caption "Adjustments to fair value of common stock warrant liability."
	Income Taxes
	The Company uses the asset and liability method of accounting for deferred income taxes. The provision for income taxes includes income taxes currently payable and those deferred as a result of temporary differences between the financial statement and tax bases of assets and liabilities. A valuation allowance is provided to reduce deferred tax assets to the amount of future tax benefit when it is more likely than not that some portion of the deferred tax assets will not be realized. Projected future taxable income and ongoing tax planning strategies are considered and evaluated when assessing the need for a valuation allowance. Any increase or decrease in a valuation allowance could have a material adverse or beneficial impact on the Company's income tax provision and net income or loss in the period which the determination is made.
	Concentration of Risks and Uncertainties
	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes that its investment policy guideline for its excess cash maintains safety and liquidity through its policies on credit requirements, diversification and investment maturity.
	The Company has experienced significant operating losses since inception. At September 30, 2014, the Company had a deficit accumulated of $229,559. The Company has generated no revenue to date. The Company has funded its operations to date principally from the sale of securities. The Company expects to incur substantial additional operating losses for the next several years and will need to obtain additional financing in order to complete the clinical development of an ultra-rapid-acting insulin or a glucagon rescue product, launch and commercialize the product if it receives regulatory approval, and continue research and development programs. There can be no assurance that such financing will be available or will be at terms acceptable to the Company.
	The Company is currently developing its first product candidates and has no products that have received regulatory approval. Any products developed by the Company will require approval from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company's products will receive the necessary approvals. If the Company is denied such approvals or such approvals are delayed, it would have a material adverse effect on the Company's future operating results.
	To achieve profitable operations, the Company must successfully develop, test, manufacture and market products, as well as secure the necessary regulatory approvals. There can be no assurance that any such products can be developed successfully or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors would have a material adverse effect on the Company's future financial results.
	Stock-Based Compensation
	In March 2013, the stockholders of the Company approved the amended and restated 2010 Stock Incentive Plan (the "2010 Plan"). Up to 3,750,000 shares of the Company's common stock may be issued pursuant to awards granted under the 2010 Plan, plus 1,540,739 shares of common stock underlying already outstanding awards under the Company's prior plans. As of September 30, 2014, the Company had a total of 2,643,523 shares of common stock subject to outstanding awards from prior and current plans. The contractual life of options granted under the 2010 Plan may not exceed seven years. The 2010 Plan uses a "fungible share" concept under which any awards that are not a full-value award will be counted against the share limit as one (1) share for each share of common stock and any award that is a full-value award will be counted against the share limit as 1.5 shares for each one share of common stock. The Company has not made any new awards under any prior equity plans after March 2, 2010, the effective date the 2010 Plan was approved by the Company's stockholders. The 2010 Plan replaces the 2004 Stock Incentive Plan and 2005 Non-Employee Directors Stock Option Plan.
	The Company uses the Black-Scholes pricing model to calculate the fair value of stock options. The expected life for grants was calculated in accordance with the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin (SAB) Topic 14.D.2 in accordance with SAB No. 110. The Company bases its estimates of expected volatility on the Company's historical volatility.
	The risk-free rate of interest for periods within the contractual life of the stock option award is based on the yield of U.S. Treasury strips on the date the award is granted with a maturity equal to the expected term of the award. The Company estimates forfeitures based on actual forfeitures during its limited history. Additionally, the Company has assumed that dividends will not be paid.
	The Company expenses ratably over the vesting period the cost of the stock options granted to employees and directors. The total compensation cost for the years ended September 30, 2013, and 2014 was $1,538, and $784 respectively. At September 30, 2014, the total compensation cost related to non-vested options not yet recognized was $1,423, which will be recognized over the next three years assuming the employees complete their service period for vesting of the options. The Black-Scholes valuation model assumptions are as follows and were determined as discussed above:
			Year Ended September 30,
			2013	2014
		Expected life (in years)	2.39 - 4.75	3.77-4.75
		Expected volatility	80 - 96%	70-83%
		Expected dividend yield	0%	0%
		Risk-free interest rate	0.25 - 0.75%	0.58-1.63%
		Weighted-average grant date fair value	$2.43	$2.35
	Participating Securities
	In June 2008 the Financial Accounting Standards Board ("FASB") issued ASC 260-10-55 Earnings Per Share — Overall (formerly Financial Statement Position Emerging Issues Task Force 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities) ("ASC 260-10-55"). ASC 260-10-55 provides that securities and unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method.
	Warrant Liability — Given that the warrant holders will participate fully on any dividends or dividend equivalents, the Company determined that the warrants are participating securities and therefore are subject to ASC 260-10-55. These securities were excluded from the per share calculation for all years since their inclusion would be anti-dilutive.
	Restricted Stock Units — Given that the holders of Restricted Stock Unit awards ("RSUs") will only receive dividends or dividend equivalents on RSUs that have vested prior to the Company declaring dividends as well as forfeiting their rights to receive dividends or dividend equivalents on any unvested portion, the Company determined that the RSUs are non-participating securities and therefore are not subject to ASC 260-10-55.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Sep. 30, 2014
Fair Value of Financial Instruments [Abstract]
Fair Value Measurements	4. Fair Value Measurement
	ASC Topic 820 ("ASC 820"), originally issued as SFAS No. 157, Fair Value Measurements, applies under other accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, ASC 820 does not require any new fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. The three levels of inputs used are as follows:
	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	As of September 30, 2013 and 2014, the Company had assets and liabilities that fell under the scope of ASC 820. The fair value of the Company's warrant liability was determined by the Black-Scholes valuation model for the warrants issued in connection with the Company's May 2011 and June 2012 financings. Accordingly, the Company's fair value measurements of its warrant liability is classified as a Level 3 input.
	The fair value of the Company's financial assets and liabilities carried at fair value and measured on a recurring basis are as follows:
		Description					Fair Value at			Quoted Prices in		Significant		Significant
							September 30,			Active Markets for		Other		Unobservable
							2014			Identical Assets		Observable		Inputs
										(Level 1)		Market Inputs		(Level 3)
												(Level 2)
		Assets:
		Cash and cash equivalents				$	24,588		$	24,588		—		—
		Subtotal					24,588			24,588		—		—
		Liabilities:
		Common stock warrant liability					(1,014	)		—		—		(1,014	)
		Subtotal					(1,014	)		—		—		(1,014	)
		Total				$	23,574		$	24,588	$	—	$	(1,014	)
		Description					Fair Value at			Quoted Prices in		Significant		Significant
							September 30,			Active Markets for		Other		Unobservable
							2013			Identical Assets		Observable		Inputs
										(Level 1)		Market Inputs		(Level 3)
												(Level 2)
		Assets:
		Cash and cash equivalents				$	39,781		$	39,781	$	—	$	—
		Subtotal					39,781			39,781		—		—
		Liabilities:
				·
		Common stock warrant liability					(6,121	)		—		—		(6,121	)
		Subtotal					(6,121	)		—		—		(6,121	)
		Total				$	33,660		$	39,781	$	—	$	(6,121	)
	The Company recognizes transfers into and out of the levels indicated above on the actual date of the event or change in circumstances that caused the transfer of change. All changes within Level 3 can be found in the following Level 3 reconciliation table:
		Balance at September 30, 2012				$	(7,338	)
		Decrease in fair value					1,217
		Balance at September 30, 2013					(6,121	)
		Decrease in fair value....................................................................................					5,107
		Balance at September 30, 2014.........................................................................				$	(1,014	)
	The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company's statement of operations. A financial instrument's level within the fair
	value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.
	Fair Value Assumptions Used in Accounting for Warrant Liability
	The Company has determined its warrant liability to be a Level 3 fair value measurement and used the Black Scholes valuation model to calculate the fair value for the fiscal year ended September 30, 2013 and 2014.
	At the measurement date, the Company estimated the fair value for the June 2012 warrants using the Black-Scholes valuation model using the following assumptions:
				September 30,			September 30,
				2013			2014
		June 2012 Financing
		Stock price	$	3.15			$1.67
		Exercise price	$	2.66			$2.66
		Risk-free interest rate		0.63	%		1.07%
		Expected remaining term		3.74 years			2.74 years
		Expected volatility		82	%		61%
		Dividend yield		0	%		0%
		Warrants outstanding June 2012 financing		2,749,469			2,749,469
	The Company estimated the fair value for the May 2011 warrants using the Black-Scholes valuation model at the measurement dates of September 30, 2013 and 2014, respectively using the following assumptions:
							September 30,			September 30,
							2013			2014
		May 2011 Financing
		Stock price					$3.15			$1.67
		Exercise price					$9.92			$9.92
		Risk-free interest rate					0.63%			0.58%
		Expected remaining term					2.63 years			1.63 years
		Expected volatility					77%			62%
		Dividend yield					0%			0%
		Warrants outstanding May 2011 financing					2,256,929			2,256,929
Risk-Free Interest Rate. This is the United States Treasury rate for the measurement date having a term equal to the expected remaining term of the warrant. An increase in the risk-free interest rate will increase the fair value and the associated derivative liability.
Expected Remaining Term. This is the remaining contractual life of the warrant.
Expected Volatility. This is a measure of the amount by which the stock price has fluctuated or is expected to fluctuate. Since the Company's stock has been traded for the expected remaining term of the warrants, the Company uses its own historic volatility over the retrospective period corresponding to the expected remaining term of the warrants on the measurement date. An increase in the expected volatility will increase the fair value and the associated derivative liability.
Dividend Yield. The Company has not made any dividend payments nor does it have plans to pay dividends in the foreseeable future. An increase in the dividend yield will decrease the fair value and the associated derivative liability.

Net_Loss_per_Share

Net Loss per Share	12 Months Ended
	Sep. 30, 2014
Net Loss Per Share [Abstract]
Net Loss per Share	5. Net Loss per Share
	Net loss per share information is determined using the two-class method, which includes the weighted-average number of common shares outstanding during the period and other securities that participate in dividends ("participating securities"). The Company considers the outstanding warrants participating securities because they include rights to participate in dividends with the common stock on a one-for-one basis. In applying the two-class method, earnings are allocated to both common stock shares and warrants based on their respective weighted-average shares outstanding for the period. Since losses are not allocated to the participating securities, the two-class method results in the same loss per common share calculated using the basic method for the periods presented in these financial statements.
	Basic and diluted net loss per share has been calculated by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive.
	The amount of options, warrants, shares of preferred stock and restricted stock units excluded are as follows:
				Year Ended September 30,
			2013		2014
		Common shares issuable upon conversion of Series B	1,950,000		1,950,000
		Preferred Stock
		Common shares underlying warrants issued for common stock	5,006,398		5,006,398
		Stock options	1,920,051		2,643,523
		Restricted stock units	31,296		—

Property_and_Equipment

Property and Equipment	12 Months Ended
	Sep. 30, 2014
Property and Equipment [Abstract]
Property and Equipment	6. Property and Equipment
	Property and equipment consists of the following:
				September 30,
				2013		2014
		Furniture and fixtures	$	324	$	324
		Leasehold improvements		1,548		1,548
		Laboratory equipment		2,062		2,112
		Manufacturing equipment		655		655
		Facility equipment		65		65
		Computer equipment and other		1,308		1,308
		Sub-Total		5,962		6,012
		Less: Accumulated depreciation and amortization		4,931		5,531
		Total	$	1,031	$	481
	Depreciation expense for the years ended September 30, 2013, and 2014 was $638, and $599, respectively.

Commitments

Commitments	12 Months Ended
	Sep. 30, 2014
Commitments [Abstract]
Commitments	7. Commitments
	Chief Executive Officer Employment Agreement
	On March 30, 2010, the Company announced the appointment of Errol B. De Souza, Ph.D., as the Company's President, Chief Executive Officer and a Director. In connection with his appointment, Dr. De
	Souza signed an employment agreement, dated March 26, 2010, setting forth the terms of his employment. The agreement provided for an initial term of employment for the period from March 29, 2010 to March 28, 2014 and it continues for successive one-year terms unless the agreement is terminated by either party on 120 days prior written notice in accordance with the terms of the agreement. The agreement provides for an annual salary of $450 and eligibility for a target bonus of 50% of the annual salary. In addition, Dr. De Souza was granted options to purchase 175,000 shares of the Company's common stock pursuant to the Company's 2010 Plan. These options were fully vested as of March 2014.
	The Company may terminate the agreement with or without cause. Dr. De Souza will not be entitled to severance benefits if the Company terminates his employment for cause, or if he terminates his employment without good reason, as defined in the agreement. If the Company terminates Dr. De Souza's employment without cause, or he terminates his employment with the Company for good reason, he is entitled to:
	•two times his then current salary, plus two times his target annual bonus for the fiscal year in which he is terminated, plus the pro rata amount of his target annual bonus for the fiscal year in which he is terminated;
	•COBRA benefits until the earlier of the end of the 24th month after the date his employment with the Company ends or the date his COBRA coverage expires;
	•24 months of acceleration of his outstanding equity compensation awards; and
	•full vesting of his outstanding equity compensation awards, if the Company terminates his employment without cause, or he resigns within 12 months following a change in control, as defined in the agreement.
	Change in Control and Severance Agreements
	Certain employees have agreements which provide for payouts in the event that the Company consummates a change in control. The amount of compensation due as a result of this event is approximately $3,501, as set forth in the agreements. These employees are also entitled to full vesting of their outstanding equity awards. These agreements also provide for routine severance compensation. As of September 30, 2014 and September 30, 2013, no amounts have been accrued.
	Leases
	As of September 30, 2014, the Company leased three facilities in Danbury, Connecticut.
	The Company renewed its lease for laboratory space for one year on October 10, 2014. This lease provides for annual basic lease payments from February 1, 2015 through January 31, 2016 of $68, plus the annual Consumers Price Index ("CPI") increase for October, not to exceed 6%, plus operating expenses.
	The Company renewed its lease agreement for additional office space adjacent to its laboratory space for one year on October 10, 2014. This lease provides for annual basic lease payments from February 1, 2015 through January 31, 2016 of $31, plus the annual CPI increase for October, not to exceed 6%, plus operating expenses.
	The Company renewed its lease for its corporate office for five years on November 6, 2013. This lease provides for annual basic lease payments from August 1, 2014 through July 31, 2019 of $388, plus the annual CPI increase for May, not to exceed 6%, plus operating expenses. Escalations shall be on an annual basis from August 1, 2015 through July 31, 2019, and will be calculated using the preceding year's basic lease payment, plus the annual CPI increase for May, not to exceed 6%.
	Lease expense for the years ended September 30, 2013, and 2014 was $646, and $627, respectively.
	Minimum lease payments under these agreements as of September 30, 2014, as well as equipment leases subsequently entered into, are as follows:
		Years Ending September 30,
		2015		683
		2016		598
		2017		558
		2018		564
		2019		480
		Total	$	2,883
	Purchase Commitments
	Commercial Supply Agreement with Bachem Americas
	The Company has entered into a commercial supply agreement for the supply of glucagon with Bachem Americas, a supplier of glucagon. The Company is obligated to purchase certain quantities of glucagon pursuant to a rolling forecast submitted by the Company under this agreement. At this time, the Company is obligated to purchase $392 of glucagon in fiscal year 2015. There is no obligation after 2015.
	Customization and Commercial Supply Agreement with Unilife Medical Solutions, Inc.
	The Company has entered into a customization and commercial supply agreement with Unilife Medical Solutions, Inc. ("Unilife"), a wholly owned subsidiary of Unilife Corporation, a company which designs, develops and manufactures advanced drug delivery devices. The agreement obligates Unilife to develop and supply dual-chamber reconstitution devices to be used with the Company's glucagon rescue product candidate. The Company is obligated to make payments to Unilife on the achievement of certain development milestones, including a payment of $750 upon the delivery of registration batches for the Company's glucagon rescue product candidate. The Company anticipates the milestone to be met in fiscal year 2015.
	Manufacturing Agreement with Cangene bioPharma
	The Company has entered into manufacturing agreement with Cangene bioPharma Inc., doing business as Emergent BioSolutions, or Emergent, under which Emergent will fill and finish the GEM device, using lyophilized glucagon and an aqueous diluent. During the term of the agreement following validation of the manufacturing process, the Company is required to purchase, and Emergent is obligated to deliver to the Company, one manufactured lot of the GEM device every quarter beginning in the third quarter of fiscal year 2017. The Company expects to reserve and commit to additional manufacturing capacity with Emergent following the commercial launch of our GEM product candidate, if successful. Either party may terminate the agreement without cause upon thirty-six months prior written notice.
	Agreement with Aegis Therapeutics
	In June 2012, the Company entered into an agreement with Aegis Therapeutics, LLC, or Aegis, to acquire an exclusive, sublicensable, worldwide license to the protein stabilization technology that it is using in the development of liquid glucagon formulations. Under the terms of the agreement, Aegis will prepare, file, prosecute and maintain patents and patent applications that are specific to the Company's liquid glucagon formulations in jurisdictions that the Company may designate from time to time. In October 2014, the Company amended this agreement to require the Company to pay Aegis $25 quarterly, beginning June 2015, subject to certain terms and conditions. The Company did not make any payments to Aegis during fiscal year 2014.
	Other Commitments
	The Company has entered into certain licensing and collaboration agreements for products currently under development. The Company may be obligated in future periods to make additional payments, which
	would become due and payable only upon the achievement of certain research and development, regulatory, and approval milestones. The specific timing of such milestones cannot be predicted and depend upon future discretionary research and clinical developments, as well as, regulatory agency actions. Further, under the terms of certain agreements the Company may be obligated to pay commercial milestones contingent upon the realization of sales revenues and sublicense revenues. Due to the long range nature of such commercial milestones, they are neither probable at this time nor predictable, and consequently are not considered contingent milestone payment amounts.
	The following table represents the Company's long term commitments:
		Years Ending September 30,
		2015(1)		1,219
		2016		127
		2017		630
		2018		1,685
		2019		3,271
		Total	$	6,932
	(1) Includes a $750 milestone payment

Income_Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2014
Income Taxes [Abstract]
Income Taxes	8. Income Taxes
	The Company files its tax returns on a fiscal year basis. For the years ended September 30, 2013 and 2014, the Company paid only state taxes.
	The provision for income taxes is as follows:
							Year Ended
							September 30,
							2013					2014
		Current expense
		Federal				$	—				$	—
		State					15					26
		Tax provision				$	15				$	26
	The following reconciles the amount of tax expense at the federal statutory rate to the tax provision (benefit) in operations:
									Year Ended September 30,
							2013								2014
		Federal statutory rate					34			%					34	%
		Federal taxes at statutory rate				$	(6,569			)				$	(4,796	)
		Tax expense on permanent differences (a)					163								(1,475	)
		State taxes, net of federal tax effect					10								17
		Valuation allowance increase (b)					6,439								6,316
		Other					(28			)					(36	)
		Actual tax provision				$	15							$	26
	____________
	(a) Permanent differences were derived from share based compensation and adjustments to common stock warrant liability.
	(b) Net of the Section 382 Adjustment.
	The following table summarized the activity related to the Company's liabilities for uncertain tax positions:
							Year Ended September 30,
							2013					2014
		Balance, beginning of year				$	75				$	75
		Decrease related to prior year's tax position					—					(75	)
		Balance, at end of year				$	75				$	—
	The Company files U.S. federal and state tax returns and has determined that its major tax jurisdictions are the United States and Connecticut. The tax years through 2014 remain open due to net operating loss and are subject to examination by the appropriate governmental agencies in the United States and Connecticut carry-forwards.
	As of September 30, 2014, the Company had net operating loss ("NOL") carry-forwards of approximately $71,898 (net of Section 382 limitation discussed below) for U.S. federal tax purposes and $126,484 for state tax purposes. These loss carry-forwards expire between 2024 and 2034. To the extent these net operating loss carry-forwards are available, the Company intends to use them to reduce the corporate income tax liability associated with its operations.
	The ability of the Company to utilize its NOL carry-forwards to reduce future taxable income is subject to various limitations under the Internal Revenue Code Section 382 ("Section 382"). The utilization of such carry-forwards may be limited upon the occurrence of certain ownership changes, including the purchase or sale of stock by 5% shareholders and the offering of stock by the Company during any three-year period resulting in an aggregate change of more than 50% in the beneficial ownership of the Company. In the event of an ownership change, Section 382 imposes an annual limitation on the amount of a Company's taxable income that can be offset by these carry-forwards. As of September 30, 2011, the Company completed a study of the impact of Section 382 limitation on future payments and determined that the statutory provisions limited the Company's ability to realize future tax benefits. Accordingly, the Company decreased federal net operating loss carry-forwards by approximately $55,929 and federal research and development credit carry-forwards by $1,817. The Company completed an additional study of the impact of Section 382 limitation on future payments in November 2013 and determined that there were no additional limitations on the Company's existing NOLs.
	The Company also has state research and development credit carry-forwards of approximately $348, which expire commencing in fiscal 2022.The major components of deferred tax assets and valuation allowances and deferred tax liabilities at September 30, 2013 and 2014 are as follows:
				September 30,
				2013					2014
		Deferred Tax Assets
		Net operating losses	$	25,149				$	30,706
		Capitalized expense		28,913					30,762
		Research and development credits		224					230
		Depreciation of fixed assets		445					467
		Other		283					196
		Total deferred tax asset		55,014					62,361
		Valuation Allowance		(55,014	)				(62,361	)
		Net Deferred Tax Assets	$	—				$	—
	Due to the substantial doubt related to Biodel's ability to continue as a going concern and utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established as of September 30, 2013 and 2014.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity	9. Stockholders' Equity
	Common Stock
	The Company's authorized common stock consists of 62,500,000 shares of a single class of common stock, having a par value of $0.01 per share. The holders of the common stock are entitled to one vote for each share and have no cumulative voting rights or preemptive rights.
	Preferred Stock
	The Company is authorized to issue up to 50,000,000 shares of preferred stock, having a par value of $0.01 per share. The Company's preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by the Company's Board of Directors, without further action by stockholders, and may include voting rights (including the right to vote as a series on particular matters), preferences as to dividends and liquidation and conversion, redemption rights and sinking fund provisions. The issuance of preferred stock could reduce the rights, including voting rights, of the holders of common stock and, therefore, could reduce the value of the common stock. In particular, specific rights granted to holders of preferred stock could be used to restrict the Company's ability to merge with or sell the Company's assets to a third party, thereby preserving control of the Company by existing management.
	Financings
	July 2014 Purchase Agreement
	On July 25, 2014, the Company entered into a purchase agreement (the "Purchase Agreement"), together with a registration rights agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Under the terms, and subject to the conditions of the Purchase Agreement, the Company has the right to sell to LPC, and LPC is obligated to purchase, up to $15 million in shares of common stock, subject to certain limitations, from time to time over the 36-month period commencing on the date that a registration statement, which the Company agreed to file with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed. The Company's registration statement was declared effective on September 2, 2014. The Company was obligated, within twenty (20) calendar days, to file with the SEC an initial Registration Statement covering the maximum number of Registrable Securities as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and LPC in consultation with their respective legal counsel, subject to the aggregate number of authorized shares of the Company's Common Stock then available for issuance in its Certificate of Incorporation. The Company shall use its commercially reasonable efforts to keep the Registration Statement effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Investor of all of the Registrable Securities covered thereby at all times until the date on which LPC shall have resold all the Registrable Securities covered thereby and no Available Amount remains under the Purchase Agreement. The Company may direct LPC, at its sole discretion and subject to certain conditions, to purchase up to 150,000 shares of common stock in any business day, increasing to amounts of up to 250,000 shares, depending upon the closing sale price of the common stock. In addition, the Company may direct LPC to purchase additional shares as accelerated purchases if, on the date of a regular purchase, the closing sale price of the common stock is not below $2.50 per share (subject to adjustment). The purchase price of shares of common stock to be purchased under the Purchase Agreement are based on the prevailing market prices of such shares at the time of sales, but in no event will the Company be able to sell shares to LPC on a day when the closing sale price of the common stock is less than a floor price of $1.50 per share (subject to adjustment). The Company will control the timing and amount of any sales of common stock to LPC under the Purchase Agreement. As consideration for LPC's commitment to purchase shares of common stock pursuant to the Purchase Agreement, the Company issued to LPC 95,000 shares of Common Stock as commitment shares, with a fair market value of $189, which is recorded as the cost of capital in additional paid in capital. As of September 30, 2014, the Company sold 300,000 shares of common stock pursuant to the Purchase Agreement, and received proceeds, net of expenses, of $490. During the period from October 1, 2014 through the date of this filing, the Company sold an aggregate of 300,000 shares of common stock pursuant to the Purchase Agreement, and received proceeds, net of expenses, of $468.
	May 2013 At-the-Market Issuance Sales Agreement
	In May 2013, the Company entered into an At-the-Market Issuance Sales Agreement (the "Sales Agreement") with MLV & Co. LLC ("MLV"), under which the Company may initially issue and sell shares of common stock having aggregate sales proceeds of up to $14 million from time to time through MLV as the Company's sales agent. For the year ended September 30, 2014, the Company sold an aggregate of 1,564,821 shares of common stock pursuant to the Sales Agreement and received proceeds, net of sales agent commissions and expenses, of $3.0 million. During the period from October 1, 2014 through the date of this filing, the Company sold an aggregate of 66,057 shares of common stock pursuant to the Sales Agreement, and received proceeds, net of expenses, of $100.
	June 2013 Public Offering
	On June 24, 2013, the Company completed an underwritten public offering of 4,482,760 shares of its common stock at a price to the public of $4.35 per share. On July 22, 2013, the Company issued 236,007 additional shares of common stock, at the public offering price of $4.35 per share, in connection with the underwriters' exercise of a portion of their over-allotment option. The Company received net proceeds from this offering, after deducting underwriting discounts, commissions and expenses, of $19.2 million.
	June 2012 Private Placement
	On June 27, 2012 the Company completed a private placement (the "2012 Private Placement") of an aggregate of 4,250,020 shares of common stock, 3,605,607 shares of Series B preferred stock and warrants to purchase 2,749,469 shares of common stock at an exercise price of $2.66 per share. For each unit consisting of either, a share of common stock or Series B preferred stock and a warrant to purchase 0.35 of a share of common stock, the purchasers in the June 2012 Private Placement paid a negotiated price of $2.355. The warrants are immediately exercisable and will expire on June 26, 2017, five years from the original issuance date of June 27, 2012.
	Each share of Series B preferred stock is convertible into one share of the Company's common stock at any time at the option of the holder, except that the securities purchase agreement that the Company entered into in connection with the 2012 Private Placement (the "Securities Purchase Agreement") provides that a holder will be prohibited from converting shares of Series B preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company's liquidation, dissolution or winding up, holders of the Series B preferred stock will receive a payment equal to $0.01 per share of Series B preferred stock before any proceeds are distributed to the holders of common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock specifically ranking by its terms senior to the Series B preferred stock, holders of Series B preferred stock and holders of the Company's Series A preferred stock will participate ratably in the distribution of any remaining assets with the common stock and any other class or series of capital stock that participates with the common stock in such distributions. Shares of Series B preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series B preferred stock will be required to amend the terms of the Series B preferred stock. Holders of Series B preferred stock are entitled to receive, and the Company is required to
	pay, dividends on shares of the Series B preferred stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividends in the form of common stock) are paid on shares of the common stock.
	As required by the Securities Purchase Agreement, the Company filed a Registration Statement on Form S-3 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") on July 27, 2012, which was within 30 days after the closing of the 2012 Private Placement. The Registration Statement, which was declared effective on August 13, 2012, registers the resale of the shares of common stock and Series B preferred stock issued and sold in the 2012 Private Placement, the shares of common stock issuable upon conversion of the Series B preferred stock issued and sold in the 2012 Private Placement, and the shares of common stock issuable upon exercise of the warrants issued and sold in the 2012 Private Placement. Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to pay liquidated damages to the purchasers in the 2012 Private Placement if, after effectiveness of the Registration Statement and subject to certain specified exceptions, the Company suspends the use of the Registration Statement or the Registration Statement ceases to remain continuously effective as to all the securities for which it is required to be effective (each such event, a "Registration Default"). Subject to specified exceptions, for each 30-day period or portion thereof during which a Registration Default remains uncured, the Company is obligated to pay liquidated damages to each purchaser in cash in an amount equal to 1.0% of the aggregate purchase price paid by each such purchaser in the 2012 Private Placement, up to a maximum of 8.0% of such aggregate purchase price. As of the date of these financial statements, the Company does not believe that it is probable that it will be obligated to pay any such liquidated damages. Accordingly, the Company has not established an accrual for liquidated damages.
	The Company received net proceeds, after deducting placement agent fees and other offering expenses of approximately $17,100 from this financing. In June 2013, 176,964 shares of the Company's Series B preferred stock were converted into an equal number of shares of common stock. In September 2013, 1,478,643 shares of the Company's Series B preferred stock were converted into an equal number of shares of common stock. As of September 30, 2014, the Company has 1,950,000 shares of the Series B preferred stock outstanding.
	In the event that the Company enters into a merger or change of control transaction, the holders of the warrants issued in the 2012 Private Placement will be entitled to receive consideration as if they had exercised the warrants immediately prior to such transaction, or they may require the Company to purchase the unexercised warrants at the Black-Scholes value (as defined in the warrant) of the warrant on the date of such transaction. The holders have up to 30 days following any such transaction to exercise this right. As a result of this provision, the Company recognizes the warrants as liabilities at their fair value on each reporting date.
	May 2011 Registered Direct Offering
	On May 12, 2011, the Company completed a registered direct offering of an aggregate of 3,018,736 shares of common stock, 1,813,044 shares of Series A preferred stock to one investor and warrants to purchase 2,256,929 shares of common stock at an exercise price of $9.92 per share. The investor who purchased Series A preferred stock units received units consisting of one share of Series A preferred stock and a warrant to purchase 0.1625 of a share of common stock. No fractional warrants were issued. Each unit was sold at a price of $8.84 per unit.
	Each share of Series A preferred stock was convertible into 0.25 of a share of the Company's common stock at any time at the option of the holder, provided that the holder would be prohibited from converting the shares of
	Series A preferred stock into shares of the Company's common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.98% of the total number of shares of the Company's common stock then issued and outstanding. In the event of the Company's liquidation, dissolution or winding up, holders of the Series A preferred stock would receive a payment equal to $0.01 per
	share of Series A preferred stock before any proceeds are distributed to the holders of the Company's common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock specifically ranking by its terms senior to the Series A preferred stock, holders of Series A preferred stock and holders of the Company's Series B preferred stock will participate ratably in the distribution of any remaining assets with the Company's common stock and any other class or series of capital stock that participates with the common stock in such distributions. Shares of Series A preferred stock generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series A preferred stock will be required to amend the terms of the Series A preferred stock. The Series A preferred stock will not be entitled to receive any dividends, unless and until specifically declared by the Company's board of directors.
	The Company received net proceeds, after deducting placement agent fees and other offering expenses, of approximately $28,000 from this financing. As of September 2013, all of the Company's Series A preferred stock was converted into 453,483 shares of common stock.
	In the event that the Company enters into a merger or change of control transaction, the holders of the warrants issued in the May 2011 financing will be entitled to receive consideration as if they had exercised the warrant immediately prior to such transaction, or they may require the Company to purchase the unexercised warrants at the Black-Scholes value (as defined in the warrant) of the warrant on the date of such transaction. As per the terms of the warrants, the holders have up to 30 days following any such transaction to exercise this right. As a result of this provision, the Company recognizes the warrants as liabilities at their fair value on each reporting date.
	The Company's warrant liability is marked-to-market each reporting period with the change in fair value recorded as a gain or loss within Other (Income) Expense ("Adjustments to fair value of common stock warrant liability"), until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified as an equity instrument.
	2004 Stock Incentive Plan
	The Company established the 2004 Stock Incentive Plan on October 1, 2004 (the "Plan"), as amended in March 2007, and subsequently replaced by the 2010 Stock Incentive Plan. The Plan provides for the granting of shares of common stock or securities convertible into or exercisable for shares of common stock, including stock options ("Incentive Stock Options") to directors, employees, consultants and advisors of or to the Company. Incentive Stock Options can be awarded only to persons who are employees of the Company at the time of the grant. Stock options are exercisable at the conclusion of the vesting period. Employees can exercise their vested shares up to 90 days after termination of services. No awards may be granted under the Plan after the effective date of the 2010 Plan.
	The Plan is administered by either the Board of Directors of the Company or a Committee thereof, which determines the terms and conditions of the awards granted under the Plan, including the recipient of the award, the nature of the award, the exercise price of the award, the number of shares subject to the award and the exercisability thereof.
	Non-employee directors are not entitled to receive awards other than the non-qualified stock options the plan directs be issued to non-employee directors.
	2010 Stock Incentive Plan
	In March 2013, the stockholders of the Company approved the amended and restated 2010 Stock Incentive Plan (the "2010 Plan"). Up to 3,750,000 shares of the Company's common stock may be issued pursuant to awards granted under the 2010 Plan, plus 1,540,739 shares of common stock underlying already outstanding awards under the Company's prior plans. As of September 30, 2014, the Company had 2,643,523
	shares of common stock subject to outstanding awards. The contractual life of options granted under the 2010 Plan may not exceed seven years. The 2010 Plan uses a "fungible share" concept under which any awards that are not a full-value award will be counted against the share limit as one (1) share for each share of common stock and any award that is a full-value award will be counted against the share limit as 1.5 shares for each one share of common stock. The Company has not made any new awards under any prior equity plans after March 2, 2010 — the effective date the 2010 Plan was approved by the Company's stockholders. The 2010 Plan replaces the 2004 Stock Incentive Plan and 2005 Non-Employee Directors Stock Option Plan.
	2005 Employee Stock Purchase Plan
	The Company's 2005 Employee Stock Purchase Plan, or the Purchase Plan, was adopted by its Board of Directors and approved by its stockholders on March 20, 2007. The Purchase Plan became effective upon the closing of the Company's initial public offering. The Purchase Plan is intended to qualify as an employee stock purchase plan within the meaning of Section 423 of the Code.
	Under the Purchase Plan, eligible employees may contribute up to 15% of their eligible earnings for the period of that offering for the purchase of common stock under the Purchase Plan. The employee's purchase price is equal to the lower of: 85% of the fair market value per share on the start date of the offering period in which the employee is enrolled or 85% of the fair market value per share on the semi-annual purchase date. The Purchase Plan imposes a limitation upon a participant's right to acquire common stock if immediately after the purchase, the employee would own 5% or more of the total combined voting power or value of the Company's common stock or of any of its affiliates not eligible to participate in the Purchase Plan. The Purchase Plan provides for an automatic rollover when the purchase price for a new offering period is lower than previously established purchase price(s). The Purchase Plan also provides for a one-time election that allows an employee the opportunity to enroll into a new offering period when the new offering is higher than their current offering price. This election must be made within 30 days from the start of a new offering period. Offering periods are twenty-seven months in length. The compensation cost in connection with the plan for the years ended September 30, 2013 and 2014 was $5 and $4 respectively.
	An aggregate of 500,000 shares of common stock are reserved for issuance pursuant to purchase rights to be granted to the Company's eligible employees under the Purchase Plan. The Purchase Plan shares are replenished annually on the first day of each fiscal year by virtue of an evergreen provision. The provision allows for share replenishment equal to the lesser of 1% of the total number of shares outstanding on that date or 25,000 shares. As of September 30, 2013 and 2014, a total of 366,926 and 383,737 shares, respectively, were reserved and available for issuance under this plan. For the years ended September 30, 2013 and 2014, the Company issued a total of 108,074, and 116,263 shares, respectively, under the Purchase Plan.
	2005 Non-Employee Directors' Stock Option Plan
	The Company's 2005 Non-Employee Directors' Stock Option Plan (the "Directors' Plan") was adopted by its Board of Directors and approved by its stockholders on March 20, 2007 and subsequently replaced with the 2010 Stock Incentive Plan. The Directors' Plan became effective upon the closing of the Company's initial public offering. An aggregate of 125,000 shares of common stock were reserved for issuance under the Directors' Plan. Upon the effective date of the registration statement in connection with the Company's initial public offering, each of its non-employee directors automatically received an initial option to purchase 6,250 shares of common stock. Upon appointment, non-employee directors receive a one-time grant of an option to purchase 6,250 shares of common stock. Annually, non-employee directors receive an option to purchase 10,000 shares of common stock. Effective March 3, 2009, these shares vest pro rata over one year. However, in the event a non-employee director has not served since the date of the preceding annual meeting of stockholders, that director will receive an annual grant that has been reduced pro rata for each full quarter prior to the date of grant during which such person did not serve as a non-employee director.
	The following table summarizes all stock option activity through September 30, 2014:
		Options	Number				Weighted		Weighted		Aggregate
							Average		Average		Intrinsic Value
							Exercise Price		Remaining
									Contractual
									Life in Years
		Outstanding balance September 30, 2012	1,546,454			$	27.8				—
		Granted	486,000				2.43				—
		Exercised	(30,250	)			2.48				—
		Forfeited, expired	(82,153	)			15.37				—
		Outstanding balance September 30, 2013	1,920,051			$	22.31		4	$	445
		Granted	1,427,000				2.35		6		—
		Exercised	(19,241	)			2.48		5		10
		Forfeited, expired	(684,287	)			16.48				—
		Outstanding balance September 30, 2014	2,643,523			$	13.15		5		—
		Exercisable shares, September 30, 2014	1,217,854			$	25.81		3		—
	Restricted Stock Units
	The Company grants restricted stock units ("RSUs") to executive officers and employees pursuant to the 2010 Plan from time to time. There is no direct cost to the recipients of RSUs, except for any applicable taxes.
	In December 2010, the Company issued RSU awards to our executive officers and employees. Each RSU award represents one share of common stock and each award vests annually over three years, with fifty percent vesting on the first anniversary of the date of grant and the remainder vesting in two equal installments on each anniversary thereafter. Each year following the annual vesting date, between January 1st and March 15th, the Company will issue common stock for each vested RSU. During the period when the RSU is vested but not distributed, the RSUs cannot be transferred and the grantee has no voting rights. If the Company declares a dividend, RSU recipients will receive payment based upon the percentage of RSUs that have vested prior to the date of declaration. The costs of the awards, determined as the fair market value of the shares on the grant date, are expensed per the vesting schedule outlined in the award. For example, the December 2010 RSU awards vested over three years and were expensed 50% the first year and 25% the next two years; whereas, the December 2009 RSU awards were expensed ratably over the four year vesting period.
	Based on historical experience of option cancellations, the Company has estimated an annualized forfeiture rate of 10% for all employee options and RSUs. Forfeiture rates will be adjusted over the requisite service period when actual forfeitures differ, or are expected to differ, from the estimate. As of September 30, 2014, the executives, the board of directors and employees had 418,295 vested and distributed RSUs.
	The stock-based compensation expense associated with the RSUs has been recorded in the statement of operations and in additional paid-in-capital on the balance sheets as follows:
					September 30,
							2013		2014
		Stock compensation expense — RSUs				$	363	$	54
At September 30, 2014, all of the RSU awards had vested and were distributed.
The following table summarizes RSU activity from October 1, 2012 through September 30, 2014:
		Shares				Weighted
						Average
						Grant-Date
						Fair Value
	Non-vested and outstanding balance at September 30, 2012	68,153			$	10.51
	Changes during the period:
	Shares granted	—				—
	Shares vested and issued	(36,851	)			10.26
	Shares forfeited or expired	(6	)			15.8
	Non-vested and outstanding balance at September 30, 2013	31,296				10.48
	Changes during the period:
	Shares granted	—				—
	Shares vested and issued	31,296				10.48
	Non-vested and outstanding balance at September 30, 2014	—				—
Shares Reserved for Future Issuance
As of September 30, 2014, the Company reserved shares of common stock for future issuance as follows:
	2010 stock incentive plan	5,240,202
	2005 employee stock purchase plan	500,000
	Common stock issuable upon conversion of Series B Preferred Stock	1,950,000
	Warrants issued in connection with May 2011 registered direct offering	2,256,929
	Warrants issued in connection with June 2012 private placement	2,749,469
	Total	12,696,600

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Sep. 30, 2014
Employee Benefit Plan [Abstract]
Employee Benefit Plan	10. Employee Benefit Plan
	Effective January 1, 2006, the Company established a 401(k) plan covering substantially all employees. Employees may contribute up to 100% of their salary per year (subject to maximum limit prescribed by federal tax law). The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contributions. For the years ended September 30, 2013 and 2014, the Company had not elected to make any contributions to the plan.

Subsequent_Event

Subsequent Event	12 Months Ended
	Sep. 30, 2014
Subsequent Event [Abstract]
Subsequent Event	11. Subsequent Event
	On November 11, 2014, the Company issued 131,128 restricted stock units to Errol De Souza, its CEO, in place of a discretionary cash bonus for the fiscal year ended September 30, 2014, in furtherance of the Company's cash conservation measures. The restricted stock units were valued using the market price of $1.50, which was the closing price of the Company's common stock on November 10, 2014. The Company has accrued and expensed $197 for the fiscal year ended September 30, 2014 for Errol De Souza's bonus. The restricted stock units vest in full on September 30, 2015. Vested shares will be delivered on September 30, 2015.
	See Note 9 for additional subsequent events for the fund raising relating to the July 2014 Purchase Agreement and May 2013 At-The Market Issuance Sales Agreement.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Research and Development Costs	Research and Development Costs
	The Company is in the business of research and development and, therefore, research and development costs include, but are not limited to, salaries and benefits, lab supplies, preclinical fees, clinical trial and related clinical manufacturing costs, allocated overhead costs and professional service providers. Research and development costs are expensed when incurred. Research and development costs aggregated $14,296, and $14,194 for the years ended September 30, 2013 and 2014, respectively.
Government Grants	Government Grants
	Grants received are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The Company requests cash funding under approved grants as expenses are incurred (not in advance) and report these receipts on the statement of operations as a separate line item entitled "Government Grants". The corresponding expenses are included in research and development expenses. In July and September 2012, the Company was awarded two National Institutes of Health grants for the development of a concentrated ultra-rapid-acting insulin formulation and a stable glucagon formulation for use in an artificial pancreas, in the amounts of $582 and $583, respectively. Each award was for two years.
	Work on the grant for the development of concentrated ultra-rapid-acting insulin formulation started in August 2012 and completed in June 2014. Expenses incurred and grant income were $327 and $167, for the years ended September 30, 2013 and 2014, respectively.
	Work on the grant for the stable glucagon formulation started in January 2013 and completed in June 2014. Expenses incurred and grant income were $219 and $364 for the years ended September 30, 2013 and 2014, respectively.
	The Company reported grant income of $546 and $531, for the years ended September 30, 2013 and 2014, respectively.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions including, but not limited to, accruals, forfeiture rate used in the computation of share-based compensation, deferred tax assets, and warrant liability estimated at fair value. Actual results may differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers currency on hand, demand deposits and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. As of September 30, 2013 and 2014, the Company had cash and cash equivalents of $39,781 and $24,588, respectively, which are primarily held in a premium commercial money market account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying amounts of the Company's financial instruments, which include cash and cash equivalents and accounts payable, approximate their fair values due to their short term maturities. Warrant liability is recorded at fair value.
Pre-Launch Inventory	Pre-Launch Inventory
	Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expense during the period the costs are incurred. Because all of its product candidates are in early stages of preclinical or clinical development, the Company currently expenses all purchases of pre-launch inventory as research and development, and expects to continue to do so until it can determine the probability of regulatory approval for the applicable product candidate.
	For the years ended September 30, 2013 and 2014, the Company expensed $121 and $3, respectively, of costs associated with the purchase of RHI and glucagon as research and development expense after such materials passed quality control inspection by the Company and transfer of title occurred.
Intellectual Property	Intellectual Property
	Intangible assets consist primarily of capitalized costs associated with the Company's ultra-rapid-acting insulin patents and the purchase of two domain addresses. They are amortized using the straight-line method over twenty years. If the Company determines that a patent will not result in future revenues, the cost related to such patent will be expensed in full on the date of that determination. Intellectual property amortization expense was $3 for each of the years ended September 30, 2013 and 2014.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation or amortization. Major improvements are capitalized, while maintenance and repairs are expensed in the period the cost is incurred. Property and equipment are depreciated over their estimated useful lives using the straight-line method. Leasehold improvements are amortized using the straight-line method over their estimated useful lives, or the remaining term of the lease, whichever is shorter. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in other income (expense) in the statement of operations. Estimated useful lives for each asset category are as follows: Furniture and fixtures — 7 years; Leasehold improvements — estimated useful life or remaining term of lease, whichever is shorter; Laboratory equipment — 7 years; Manufacturing equipment — 5 years; Device development— 5 years; Facility equipment— 3 years and 7 years; Computer equipment — 5 years; and Computer software — 3 years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	Whenever events or changes in circumstances indicate that the carrying amounts of a long-lived asset may not be recoverable, the Company reviews these assets for impairment and determines whether adjustments are needed to carrying values. There were no adjustments to the carrying value of long-lived assets at September 30, 2013 and 2014.
Warrant Liability	Warrant Liability
	The Company applies the provisions of Accounting Standards Codification Topic 480 ("ASC 480") (formerly FASB Staff Position 150-5 (FSP 15-5)), Issuers Accounting under FASB Statement No. 150 for Freestanding Warrants and other Similar Instruments on Shares that are Redeemable or Distinguishing Liabilities from Equities. Pursuant to ASC 480, a freestanding financial instrument (other than outstanding share) that, at inception, embodies an obligation to repurchase the issuer's shares and "requires or may require" the obligation to be settled by transferring assets, qualifies as a liability (if the obligation is conditional, the number of conditions is irrelevant).
	The Company issued warrants in May 2011 and June 2012 and recorded a liability determined by the Black-Scholes valuation model. The Black-Scholes valuation model was used because the warrants do not contain a repricing provision. The Black-Scholes valuation model takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the term of the warrant. These warrants will be revalued at each reporting period and changes in fair value are recognized currently in the statements of operations under the caption "Adjustments to fair value of common stock warrant liability."
Income Taxes	Income Taxes
	The Company uses the asset and liability method of accounting for deferred income taxes. The provision for income taxes includes income taxes currently payable and those deferred as a result of temporary differences between the financial statement and tax bases of assets and liabilities. A valuation allowance is provided to reduce deferred tax assets to the amount of future tax benefit when it is more likely than not that some portion of the deferred tax assets will not be realized. Projected future taxable income and ongoing tax planning strategies are considered and evaluated when assessing the need for a valuation allowance. Any increase or decrease in a valuation allowance could have a material adverse or beneficial impact on the Company's income tax provision and net income or loss in the period which the determination is made.
Concentration of Risks and Uncertainties	Concentration of Risks and Uncertainties
	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes that its investment policy guideline for its excess cash maintains safety and liquidity through its policies on credit requirements, diversification and investment maturity.
	The Company has experienced significant operating losses since inception. At September 30, 2014, the Company had a deficit accumulated of $229,559. The Company has generated no revenue to date. The Company has funded its operations to date principally from the sale of securities. The Company expects to incur substantial additional operating losses for the next several years and will need to obtain additional financing in order to complete the clinical development of an ultra-rapid-acting insulin or a glucagon rescue product, launch and commercialize the product if it receives regulatory approval, and continue research and development programs. There can be no assurance that such financing will be available or will be at terms acceptable to the Company.
	The Company is currently developing its first product candidates and has no products that have received regulatory approval. Any products developed by the Company will require approval from the FDA or foreign regulatory agencies prior to commercial sales. There can be no assurance that the Company's products will receive the necessary approvals. If the Company is denied such approvals or such approvals are delayed, it would have a material adverse effect on the Company's future operating results.
	To achieve profitable operations, the Company must successfully develop, test, manufacture and market products, as well as secure the necessary regulatory approvals. There can be no assurance that any such products can be developed successfully or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors would have a material adverse effect on the Company's future financial results.
Stock-Based Compensation	Stock-Based Compensation
	In March 2013, the stockholders of the Company approved the amended and restated 2010 Stock Incentive Plan (the "2010 Plan"). Up to 3,750,000 shares of the Company's common stock may be issued pursuant to awards granted under the 2010 Plan, plus 1,540,739 shares of common stock underlying already outstanding awards under the Company's prior plans. As of September 30, 2014, the Company had a total of 2,643,523 shares of common stock subject to outstanding awards from prior and current plans. The contractual life of options granted under the 2010 Plan may not exceed seven years. The 2010 Plan uses a "fungible share" concept under which any awards that are not a full-value award will be counted against the share limit as one (1) share for each share of common stock and any award that is a full-value award will be counted against the share limit as 1.5 shares for each one share of common stock. The Company has not made any new awards under any prior equity plans after March 2, 2010, the effective date the 2010 Plan was approved by the Company's stockholders. The 2010 Plan replaces the 2004 Stock Incentive Plan and 2005 Non-Employee Directors Stock Option Plan.
	The Company uses the Black-Scholes pricing model to calculate the fair value of stock options. The expected life for grants was calculated in accordance with the simplified method described in the Securities and Exchange Commission Staff Accounting Bulletin (SAB) Topic 14.D.2 in accordance with SAB No. 110. The Company bases its estimates of expected volatility on the Company's historical volatility.
	The risk-free rate of interest for periods within the contractual life of the stock option award is based on the yield of U.S. Treasury strips on the date the award is granted with a maturity equal to the expected term of the award. The Company estimates forfeitures based on actual forfeitures during its limited history. Additionally, the Company has assumed that dividends will not be paid.
	The Company expenses ratably over the vesting period the cost of the stock options granted to employees and directors. The total compensation cost for the years ended September 30, 2013, and 2014 was $1,538, and $784 respectively. At September 30, 2014, the total compensation cost related to non-vested options not yet recognized was $1,423, which will be recognized over the next three years assuming the employees complete their service period for vesting of the options. The Black-Scholes valuation model assumptions are as follows and were determined as discussed above:
			Year Ended September 30,
			2013	2014
		Expected life (in years)	2.39 - 4.75	3.77-4.75
		Expected volatility	80 - 96%	70-83%
		Expected dividend yield	0%	0%
		Risk-free interest rate	0.25 - 0.75%	0.58-1.63%
		Weighted-average grant date fair value	$2.43	$2.35
Participating Securities	Participating Securities
	In June 2008 the Financial Accounting Standards Board ("FASB") issued ASC 260-10-55 Earnings Per Share — Overall (formerly Financial Statement Position Emerging Issues Task Force 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities) ("ASC 260-10-55"). ASC 260-10-55 provides that securities and unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method.
	Warrant Liability — Given that the warrant holders will participate fully on any dividends or dividend equivalents, the Company determined that the warrants are participating securities and therefore are subject to ASC 260-10-55. These securities were excluded from the per share calculation for all years since their inclusion would be anti-dilutive.
	Restricted Stock Units — Given that the holders of Restricted Stock Unit awards ("RSUs") will only receive dividends or dividend equivalents on RSUs that have vested prior to the Company declaring dividends as well as forfeiting their rights to receive dividends or dividend equivalents on any unvested portion, the Company determined that the RSUs are non-participating securities and therefore are not subject to ASC 260-10-55.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Black-Scholes valuation model assumptions
			Year Ended September 30,
			2013	2014
		Expected life (in years)	2.39 - 4.75	3.77-4.75
		Expected volatility	80 - 96%	70-83%
		Expected dividend yield	0%	0%
		Risk-free interest rate	0.25 - 0.75%	0.58-1.63%
		Weighted-average grant date fair value	$2.43	$2.35

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Sep. 30, 2014
Fair Value of Financial Instruments [Abstract]
Company's financial assets and liabilities carried at fair value and measured on a recurring basis
		Description					Fair Value at			Quoted Prices in		Significant		Significant
							September 30,			Active Markets for		Other		Unobservable
							2014			Identical Assets		Observable		Inputs
										(Level 1)		Market Inputs		(Level 3)
												(Level 2)
		Assets:
		Cash and cash equivalents				$	24,588		$	24,588		—		—
		Subtotal					24,588			24,588		—		—
		Liabilities:
		Common stock warrant liability					(1,014	)		—		—		(1,014	)
		Subtotal					(1,014	)		—		—		(1,014	)
		Total				$	23,574		$	24,588	$	—	$	(1,014	)
		Description					Fair Value at			Quoted Prices in		Significant		Significant
							September 30,			Active Markets for		Other		Unobservable
							2013			Identical Assets		Observable		Inputs
										(Level 1)		Market Inputs		(Level 3)
												(Level 2)
		Assets:
		Cash and cash equivalents				$	39,781		$	39,781	$	—	$	—
		Subtotal					39,781			39,781		—		—
		Liabilities:
				·
		Common stock warrant liability					(6,121	)		—		—		(6,121	)
		Subtotal					(6,121	)		—		—		(6,121	)
		Total				$	33,660		$	39,781	$	—	$	(6,121	)
Company recognizes transfers into and out of the level 3
		Balance at September 30, 2012				$	(7,338	)
		Decrease in fair value					1,217
		Balance at September 30, 2013					(6,121	)
		Decrease in fair value....................................................................................					5,107
		Balance at September 30, 2014.........................................................................				$	(1,014	)
Fair value assumptions used in accounting for warrant liability
				September 30,			September 30,
				2013			2014
		June 2012 Financing
		Stock price	$	3.15			$1.67
		Exercise price	$	2.66			$2.66
		Risk-free interest rate		0.63	%		1.07%
		Expected remaining term		3.74 years			2.74 years
		Expected volatility		82	%		61%
		Dividend yield		0	%		0%
		Warrants outstanding June 2012 financing		2,749,469			2,749,469
							September 30,			September 30,
							2013			2014
		May 2011 Financing
		Stock price					$3.15			$1.67
		Exercise price					$9.92			$9.92
		Risk-free interest rate					0.63%			0.58%
		Expected remaining term					2.63 years			1.63 years
		Expected volatility					77%			62%
		Dividend yield					0%			0%
		Warrants outstanding May 2011 financing					2,256,929			2,256,929

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	12 Months Ended
	Sep. 30, 2014
Net Loss Per Share [Abstract]
Dilutive common shares excluded from the calculation of weighted average common shares outstanding
				Year Ended September 30,
			2013		2014
		Common shares issuable upon conversion of Series B	1,950,000		1,950,000
		Preferred Stock
		Common shares underlying warrants issued for common stock	5,006,398		5,006,398
		Stock options	1,920,051		2,643,523
		Restricted stock units	31,296		—

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2014
Property and Equipment [Abstract]
Schedule of property and equipment
				September 30,
				2013		2014
		Furniture and fixtures	$	324	$	324
		Leasehold improvements		1,548		1,548
		Laboratory equipment		2,062		2,112
		Manufacturing equipment		655		655
		Facility equipment		65		65
		Computer equipment and other		1,308		1,308
		Sub-Total		5,962		6,012
		Less: Accumulated depreciation and amortization		4,931		5,531
		Total	$	1,031	$	481

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Sep. 30, 2014
Commitments [Abstract]
Schedule of minimum lease payments
		Years Ending September 30,
		2015		683
		2016		598
		2017		558
		2018		564
		2019		480
		Total	$	2,883
Schedule of long term commitments	Years Ending September 30,
		2015(1)		1,219
		2016		127
		2017		630
		2018		1,685
		2019		3,271
		Total	$	6,932
	(1) Includes a $750 milestone payment

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2014
Income Taxes [Abstract]
Schedule of Provision for income taxes
							Year Ended
							September 30,
							2013					2014
		Current expense
		Federal				$	—				$	—
		State					15					26
		Tax provision				$	15				$	26
Schedule of federal statutory rate to tax provision (benefit) in operations
									Year Ended September 30,
							2013								2014
		Federal statutory rate					34			%					34	%
		Federal taxes at statutory rate				$	(6,569			)				$	(4,796	)
		Tax expense on permanent differences (a)					163								(1,475	)
		State taxes, net of federal tax effect					10								17
		Valuation allowance increase (b)					6,439								6,316
		Other					(28			)					(36	)
		Actual tax provision				$	15							$	26
	____________
	(a) Permanent differences were derived from share based compensation and adjustments to common stock warrant liability.
	(b) Net of the Section 382 Adjustment.
Schedule of liabilities for uncertain tax positions
							Year Ended September 30,
							2013					2014
		Balance, beginning of year				$	75				$	75
		Decrease related to prior year's tax position					—					(75	)
		Balance, at end of year				$	75				$	—
Components of deferred tax assets, valuation allowances and deferred tax liabilities
				September 30,
				2013					2014
		Deferred Tax Assets
		Net operating losses	$	25,149				$	30,706
		Capitalized expense		28,913					30,762
		Research and development credits		224					230
		Depreciation of fixed assets		445					467
		Other		283					196
		Total deferred tax asset		55,014					62,361
		Valuation Allowance		(55,014	)				(62,361	)
		Net Deferred Tax Assets	$	—				$	—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2014
Stockholders' Equity [Abstract]
Summary of the stock option activity
		Options	Number				Weighted			Weighted			Aggregate
							Average			Average			Intrinsic Value
							Exercise Price			Remaining
										Contractual
										Life in Years
		Outstanding balance September 30, 2012	1,546,454			$	27.8						—
		Granted	486,000				2.43						—
		Exercised	(30,250	)			2.48						—
		Forfeited, expired	(82,153	)			15.37						—
		Outstanding balance September 30, 2013	1,920,051			$	22.31			4		$	445
		Granted	1,427,000				2.35			6			—
		Exercised	(19,241	)			2.48			5			10
		Forfeited, expired	(684,287	)			16.48						—
		Outstanding balance September 30, 2014	2,643,523			$	13.15			5			—
		Exercisable shares, September 30, 2014	1,217,854			$	25.81			3			—
Stock-based compensation expense associated with the RSUs
					September 30,
							2013			2014
		Stock compensation expense — RSUs				$	363		$	54
Summary of RSU activity
							Shares					Weighted
												Average
												Grant-Date
												Fair Value
		Non-vested and outstanding balance at September 30, 2012			68,153						$		10.51
		Changes during the period:
		Shares granted			—								—
		Shares vested and issued			(36,851			)					10.26
		Shares forfeited or expired			(6			)					15.8
		Non-vested and outstanding balance at September 30, 2013			31,296								10.48
		Changes during the period:
		Shares granted			—								—
		Shares vested and issued			31,296								10.48
		Non-vested and outstanding balance at September 30, 2014			—								—
Summary of stock reserved for future issuance
		2010 stock incentive plan	5,240,202
		2005 employee stock purchase plan	500,000
		Common stock issuable upon conversion of Series B Preferred Stock	1,950,000
		Warrants issued in connection with May 2011 registered direct offering	2,256,929
		Warrants issued in connection with June 2012 private placement	2,749,469
		Total	12,696,600

Basis_of_Presentation_and_Goin1

Basis of Presentation and Going Concern (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Basis of Presentation and Going Concern (Textual)
Proceeds from sale of common stock		$19,239
MLV & Co. [Member]
Basis of Presentation and Going Concern (Textual)
Proceeds from sale of common stock	9,200
Lincoln Park Capital Fund, LLC. [Member]
Basis of Presentation and Going Concern (Textual)
Proceeds from purchase of common stock	$14,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Summary of Significant Accounting Policies [Abstract]
Expected life (in years), Minimum	3 years 9 months 7 days	2 years 4 months 21 days
Expected life (in years), Maximum	4 years 9 months	4 years 9 months
Expected volatility, Minimum	70.00%	80.00%
Expected volatility, Maximum	83.00%	96.00%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate, Minimum	0.58%	0.25%
Risk-free interest rate, Maximum	1.63%	0.75%
Weighted-average grant date fair value	$2.35	$2.43

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	Sep. 30, 2012	Mar. 31, 2013
Summary Of Significant Accounting Policies (Textual)
Research and development	$14,194	$14,296
Period for grants awards	2 years
Grant one received from government	582
Grant two received from government	583
Insulin formulation grant expenses incurred	167	327
Glucagon formulation grant expenses incurred	364	219
Grant income	531	546
Cash and cash equivalents	24,588	39,781		39,050
Research and development expenses pertaining to RHI and glucagon	3	121
Amortization of intangible assets	3	3
Adjustment for impairment of long-lived assets
Accumulated deficit	-229,559	-215,428
Stock-based compensation for employees and directors	784	1,538
Total compensation cost related to non-vested options not yet recognized	$1,423
2010 Stock Incentive Plan
Summary Of Significant Accounting Policies (Textual)
Share-based compensation number of shares authorized					3,750,000
Share-based compensation outstanding, number	2,643,523				1,540,739
Stock incentive plan, terms			The 2010 Plan uses a "fungible share" concept under which any awards that are not a full-value award will be counted against the share limit as one (1) share for each share of common stock and any award that is a full-value award will be counted against the share limit as 1.5 shares for each one share of common stock.
Furniture and fixtures [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	7 years
Leasehold Improvements [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	Estimated useful life or remaining term of lease, whichever is shorter
Laboratory Equipment [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	7 years
Manufacturing Equipment [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	5 years
Device Development [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	5 years
Facility Equipment [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	3 years and 7 years
Computer Equipment [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	5 years
Computer software [Member]
Summary Of Significant Accounting Policies (Textual)
Estimated useful life of Property and Equipment	3 years

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Liabilities:
Common stock warrant liability	($1,014)	($6,121)
Recurring [Member]
Assets:
Cash and cash equivalents	24,588	39,781
Subtotal	24,588	39,781
Liabilities:
Common stock warrant liability	-1,014	-6,121
Subtotal	-1,014	-6,121
Total	23,574	33,660
Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Cash and cash equivalents	24,588	39,781
Subtotal	24,588	39,781
Liabilities:
Common stock warrant liability
Subtotal
Total	24,588	39,781
Recurring [Member] | Significant Other Observable Market Inputs (Level 2) [Member]
Assets:
Cash and cash equivalents
Subtotal
Liabilities:
Common stock warrant liability
Subtotal
Total
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets:
Cash and cash equivalents
Subtotal
Liabilities:
Common stock warrant liability	-1,014	-6,121
Subtotal	-1,014	-6,121
Total	($1,014)	($6,121)

Fair_Value_Measurement_Details1

Fair Value Measurement (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Reconcilliation of Level 3 changes
Beginning Balance	($6,121)	($7,338)
Decrease in fair value of common stock warrant liability	5,107	1,217
Ending Balance	($1,014)	($6,121)

Fair_Value_Measurement_Details2

Fair Value Measurement (Details 2) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
June 2012 Financing [Member]
Fair value assumptions used in accounting for warrant liability
Stock price	$1.67	$3.15
Exercise price	$2.66	$2.66
Risk-free interest rate	1.07%	0.63%
Expected remaining term	2 years 8 months 27 days	3 years 8 months 27 days
Expected volatility	61.00%	82.00%
Dividend yield	0.00%	0.00%
Warrants outstanding	2,749,469	2,749,469
May 2011 Financing [Member]
Fair value assumptions used in accounting for warrant liability
Stock price	$1.67	$3.15
Exercise price	$9.92	$9.92
Risk-free interest rate	0.58%	0.63%
Expected remaining term	1 year 7 months 17 days	2 years 7 months 17 days
Expected volatility	62.00%	77.00%
Dividend yield	0.00%	0.00%
Warrants outstanding	2,256,929	2,256,929

Net_Loss_per_Share_Details

Net Loss per Share (Details)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Common shares issuable upon conversion of Series B Preferred Stock [Member]
Dilutive common shares excluded from the calculation of weighted average common shares outstanding
Amount of options, warrants, preferred stock and RSUs	1,950,000	1,950,000
Common shares underlying warrants issued for common stock [Member]
Dilutive common shares excluded from the calculation of weighted average common shares outstanding
Amount of options, warrants, preferred stock and RSUs	5,006,398	5,006,398
Stock options [Member]
Dilutive common shares excluded from the calculation of weighted average common shares outstanding
Amount of options, warrants, preferred stock and RSUs	2,643,523	1,920,051
Restricted stock units [Member]
Dilutive common shares excluded from the calculation of weighted average common shares outstanding
Amount of options, warrants, preferred stock and RSUs		31,296

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Property and equipment
Sub-Total	$6,012	$5,962
Less: Accumulated depreciation and amortization	5,531	4,931
Total	481	1,031
Furniture and Fixtures [Member]
Property and equipment
Sub-Total	324	324
Leasehold Improvements [Member]
Property and equipment
Sub-Total	1,548	1,548
Laboratory Equipment [Member]
Property and equipment
Sub-Total	2,112	2,062
Manufacturing Equipment [Member]
Property and equipment
Sub-Total	655	655
Facility Equipment [Member]
Property and equipment
Sub-Total	65	65
Computer Equipment and other [Member]
Property and equipment
Sub-Total	$1,308	$1,308

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Property and Equipment (Textual)
Depreciation expense	$599	$638

Commitments_Details

Commitments (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Minimum lease payments
2015	$683
2016	598
2017	558
2018	564
2019	480
Total	$2,883

Commitments_Details_1

Commitments (Details 1) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Long term commitments
2015	$1,219	[1]
2016	127
2017	630
2018	1,685
2019	3,271
Total	$6,932
[1]	Includes a $750 milestone payment

Commitments_Details_Textual

Commitments (Details Textual) (USD $)	12 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Mar. 30, 2010	Oct. 31, 2014
	InsulinFacility
Commitments (Textual)
Salary, bonus and benefits paid as per employment agreement terms				$25
Number of facilities leased	3
Lease expenses	627	646
Purchase commitment	6,932
Payment to Unilife Medical Solutions, Inc	750
Chief Executive Officer Employment Agreement [Member]
Commitments (Textual)
Description of initial term of employment			March 29, 2010 to March 28, 2014
Successive renewable period			1 year
Notice period prior to expiry of term			120 days
Compensation payable for agreement			450
Percentage of target bonus			50.00%
Option granted to purchase common stock			175,000
Termination of employment without cause entitlement with Dr. De Souza, Description	1.) two times his then current salary, plus two times his target annual bonus for the fiscal year in which he is terminated, plus the pro rata amount of his target annual bonus for the fiscal year in which he is terminated; 2.) COBRA benefits until the earlier of the end of the 24th month after the date his employment with the Company ends or the date his COBRA coverage expires; 3.) 24 months of acceleration of his outstanding equity compensation awards; and 4.) full vesting of his outstanding equity compensation awards, if the Company terminates his employment without cause, or he resigns within 12 months following a change in control, as defined in the agreement.
Period of charges recorded for benefit continuation			24 months
Severance Agreement [Member]
Commitments (Textual)
Compensation amount due to change in control and severance agreements	3,501
Commercial Supply Agreement [Member]
Commitments (Textual)
Purchase commitment	392
Laboratory Space [Member]
Commitments (Textual)
Additionally period for renewal of lease	1 year
Leases amendment description	Lease provides for annual basic lease payments from February 1, 2015 through January 31, 2016 of $68, plus the annual Consumers Price Index ("CPI") increase for October, not to exceed 6%, plus operating expenses.
Annual basic lease payments plus operating expenses	68
Percentage of increase in annual Consumers Price Index (CPI)	6.00%
Office Space [Member]
Commitments (Textual)
Additionally period for renewal of lease	1 year
Leases amendment description	Lease provides for annual basic lease payments from February 1, 2015 through January 31, 2016 of $3, plus the annual CPI increase for October, not to exceed 6%, plus operating expenses.
Annual basic lease payments plus operating expenses	31
Percentage of increase in annual Consumers Price Index (CPI)	6.00%
Corporate Office [Member]
Commitments (Textual)
Additionally period for renewal of lease	5 years
Leases amendment description	Lease provides for annual basic lease payments from August 1, 2014 through July 31, 2019 of $388, plus the annual CPI increase for May, not to exceed 6%, plus operating expenses.
Annual basic lease payments plus operating expenses	$388
Percentage of increase in annual Consumers Price Index (CPI)	6.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Current expense
Federal
State	26	15
Tax provision	$26	$15

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
Reconciles of tax expense at federal statutory rate to tax provision (benefit) in operations
Federal statutory rate	34.00%		34.00%
Federal taxes at statutory rate	($4,796)		($6,569)
Tax expense on permanent differences (a)	-1,475	[1]	163	[1]
State taxes, net of federal tax effect	17		10
Valuation allowance increase (b)	6,316	[2]	6,439	[2]
Other	-36		-28
Actual tax provision	$26		$15
[1]	Permanent differences were derived from share based compensation and adjustments to common stock warrant liability.
[2]	Net of the Section 382 Adjustment.

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Liabilities for uncertain tax positions
Balance, beginning of year	$75	$75
Decrease related to prior year's tax position	-75
Balance, at end of year		$75

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Deferred Tax Assets
Net operating losses	$30,706	$25,149
Capitalized expense	30,762	28,913
Research and development credits	230	224
Depreciation of fixed assets	467	445
Other	196	283
Total deferred tax asset	62,361	55,014
Valuation Allowance	-62,361	-55,014
Net Deferred Tax Assets

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Internal Revenue Code [Member]
Income Taxes (Textual)
Portion of federal losses expire unused due to Section 382 limitation	$55,929
Expiration of net operating loss carryforwards	Loss carry-forwards expire between 2024 and 2034.
Description of net operating loss carryforwards to reduce future taxable income	The utilization of such carry-forwards may be limited upon the occurrence of certain ownership changes, including the purchase or sale of stock by 5% shareholders and the offering of stock by the Company during any three-year period resulting in an aggregate change of more than 50% in the beneficial ownership of the Company.
U.S. federal tax [Member]
Income Taxes (Textual)
Total federal losses (prior to the Section 382 limitation)	71,898
Limitations of federal research and development credit carryovers	Approximately $1,817.
State tax [Member]
Income Taxes (Textual)
Total federal losses (prior to the Section 382 limitation)	$126,484
Limitations of federal research and development credit carryovers	Approximately $348.

Stockholders_Equity_Details

Stockholders' Equity (Details) (Stock options [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Stock options [Member]
Summary of the stock option activity
Beginning balance, Outstanding options, Number	1,920,051	1,546,454
Granted, Number	1,427,000	486,000
Exercised, Number	-19,241	-30,250
Forfeited, expired, Number	-684,287	-82,153
Ending balance, Outstanding options, Number	2,643,523	1,920,051
Exercisable options, Number	1,217,854
Beginning balance, Outstanding options, Weighted Average Exercise Price	$22.31	$27.80
Granted, Weighted Average Exercise Price	$2.35	$2.43
Exercised, Weighted Average Exercise Price	$2.48	$2.48
Forfeited, expired, Weighted Average Exercise Price	$16.48	$15.37
Ending balance, Outstanding options, Weighted Average Exercise Price	$13.15	$22.31
Exercisable options, Weighted Average Exercise Price	$25.81
Beginning balance, Outstanding options, Weighted Average Remaining Contractual Life in Years	4 years
Granted, Weighted Average Remaining Contractual Life in Years	6 years
Exercised, Weighted Average Remaining Contractual Life in Years	5 years
Ending balance, Outstanding options, Weighted Average Remaining Contractual Life in Years	5 years
Exercisable options, Weighted Average Remaining Contractual Life in Years	3 years
Beginning balance, Outstanding options, Aggregate Intrinsic Value	$445
Granted, Aggregate Intrinsic Value
Exercised, Aggregate Intrinsic Value	10
Forfeited, expired, Aggregate Intrinsic Value
Ending balance, Outstanding options, Aggregate Intrinsic Value		445
Exercisable options, Aggregate Intrinsic Value

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (Restricted Stock Units [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Restricted Stock Units [Member]
Stock-based compensation expense associated with the RSUs
Stock compensation expense - RSUs	$54	$363

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (Restricted stock units (RSUs) [Member], USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Restricted stock units (RSUs) [Member]
Summary of RSUs activities
Non-vested and outstanding balance	31,296	68,153
Non-vested and outstanding balance, Weighted Average Grant-Date Fair Value	$10.48	$10.51
Changes during the period:
Shares granted, Shares
Shares granted, Weighted Average Grant-Date Fair Value
Shares vested and issued, Shares	31,296	-36,851
Shares vested and issued, Weighted Average Grant-Date Fair Value	$10.48	$10.26
Shares forfeited or expired , Shares		-6
Shares forfeited or expired, Weighted Average Grant-Date Fair Value		$15.80
Non-vested and outstanding balance		31,296
Non-vested and outstanding balance, Weighted average grant date fair value		$10.48

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3)	Sep. 30, 2014
Summary of shares reserved for future issuance
Shares reserved and available for issuance under the purchase plan	12,696,600
2010 Stock Incentive Plan [Member]
Summary of shares reserved for future issuance
Shares reserved and available for issuance under the purchase plan	5,240,202
2005 Employee Stock Purchase Plan [Member]
Summary of shares reserved for future issuance
Shares reserved and available for issuance under the purchase plan	500,000
Common shares issuable upon conversion of Series B Preferred Stock [Member]
Summary of shares reserved for future issuance
Shares reserved and available for issuance under the purchase plan	1,950,000
Warrants issued in connection with May 2011 registered direct offering [Member]
Summary of shares reserved for future issuance
Shares reserved and available for issuance under the purchase plan	2,256,929
Warrants issued in connection with June 2012 private placement [Member]
Summary of shares reserved for future issuance
Shares reserved and available for issuance under the purchase plan	2,749,469

Stockholders_Equity_Details_Te

Stockholder's Equity (Details Textual ) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jul. 25, 2014	Sep. 30, 2014	Oct. 01, 2014	31-May-13	Jun. 24, 2013	Jul. 22, 2013	Jun. 27, 2012	12-May-11	Sep. 30, 2013	Jun. 30, 2013
Stockholders Equity (Textual)
Common stock, shares authorized		62,500,000							62,500,000
Common stock, par value (in dollars per share)		$0.01							$0.01
Preferred stock, shares authorized		50,000,000							50,000,000
Preferred stock, par value (in dollars per share)		$0.01							$0.01
Purchase obligation in shares of common stock		$6,932
Common shares issued after conversion of preferred stock									453,483
Preferred stock, shares outstanding		1,950,000							1,950,000
July 2014 Purchase Agreement [Member]
Stockholders Equity (Textual)
Purchase obligation in shares of common stock	15,000
Term of purchase agreement	36 months
Number of shares issued in transaction		300,000
Stock issued as commitment shares	95,000
Stock issued as commitment shares, fair value	189
Proceeds from sale of stock		490
July 2014 Purchase Agreement [Member] | Subsequent Event [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction			300,000
Proceeds from sale of stock			468
July 2014 Purchase Agreement [Member] | Maximum [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction	250,000
Sale of stock, price per share	$2.50
July 2014 Purchase Agreement [Member] | Minimum [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction	150,000
Sale of stock, price per share	$1.50
May 2013 At-the-Market Issuance Sales Agreement [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction		1,564,821
Proceeds from sale of stock		3,000		14,000
May 2013 At-the-Market Issuance Sales Agreement [Member] | Subsequent Event [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction		66,057
Proceeds from sale of stock		100
June 2013 Public Offering [Member] | Common stock [Member]
Stockholders Equity (Textual)
Proceeds from sale of stock					19,200
June 2013 Public Offering [Member] | Common stock [Member] | IPO [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction					4,482,760
Sale of stock, price per share					$4.35
June 2013 Public Offering [Member] | Common stock [Member] | Over-Allotment Option [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction						236,007
Sale of stock, price per share						$4.35
June 2012 Private Placement [Member]
Stockholders Equity (Textual)
Negotiated price terms							For each unit consisting of either, a share of common stock or Series B preferred stock and a warrant to purchase 0.35 of a share of common stock, the purchasers in the June 2012 Private Placement paid a negotiated price of $2.355.
June 2012 Private Placement [Member] | Common stock [Member] | Private Placement [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction							4,250,020
June 2012 Private Placement [Member] | Series B Preferred Stock [Member]
Stockholders Equity (Textual)
Preferred stock, shares outstanding		1,950,000
June 2012 Private Placement [Member] | Series B Preferred Stock [Member] | Private Placement [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction							3,605,607
June 2012 Private Placement [Member] | Series B Preferred Warrants [Member]
Stockholders Equity (Textual)
Sale of stock, price per share							2.355
Warrants exercise price							2.66
Warrants issued to purchase common stock							2,749,469
Warrants expiration date							26-Jun-17
Minimum benefit owned by holder on conversion of preferred stock							9.98%
Per share payment to preferred stock holder before common stock							0.01
Convertible preferred stock, terms of conversion							Each share of Series B preferred stock is convertible into one share of the Company's common stock at any time at the option of the holder, except that the securities purchase agreement that the Company entered into in connection with the 2012 Private Placement (the "Securities Purchase Agreement") provides that a holder will be prohibited from converting shares of Series B preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company's liquidation, dissolution or winding up, holders of the Series B preferred stock will receive a payment equal to $0.01 per share of Series B preferred stock before any proceeds are distributed to the holders of common stock.
Period of filing of registration statement		Within 30 days after the closing of the 2012 Private Placement.
Declaration date of registration statement		13-Aug-12
Minimum percentage of purchase price company obligated to pay as liquidated damages		1.00%
Maximum percentage of purchase price company obligated to pay as liquidated damages		8.00%
Net proceeds from issuance of Common stock and warrant		17,100
Common shares issued after conversion of preferred stock									1,478,643	176,964
May 2011 registered direct offering [Member]
Stockholders Equity (Textual)
Minimum benefit owned by holder on conversion of preferred stock								9.98%
Per share payment to preferred stock holder before common stock								$0.01
Convertible preferred stock, terms of conversion								Each share of Series A preferred stock was convertible into 0.25 of a share of the Company's common stock at any time at the option of the holder.
Conversion of stock, description								The investor who purchased Series A preferred stock units received units consisting of one share of Series A preferred stock and a warrant to purchase 0.1625 of a share of common stock.
May 2011 registered direct offering [Member] | Common stock [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction								3,018,736
May 2011 registered direct offering [Member] | Series A Preferred Stock [Member]
Stockholders Equity (Textual)
Number of shares issued in transaction								1,813,044
May 2011 registered direct offering [Member] | Series A Warrants [Member]
Stockholders Equity (Textual)
Sale of stock, price per share								$8.84
Warrants exercise price								$9.92
Warrants issued to purchase common stock								2,256,929
Net proceeds from issuance of Common stock and warrant								$28,000

Stockholders_Equity_Details_Te1

Stockholders' Equity (Details Textual 1) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2013
Stockholders Equity Additional (Textual)
Vesting period	7 years
Shares reserved and available for issuance under the purchase plan	12,696,600
Restricted Stock Units [Member]
Stockholders Equity Additional (Textual)
Vesting period	4 years
Compensation cost in connection with the purchase plan	54	$363
Annual forfeiture rate for employee and director options	10.00%
Shares vested	31,296	-36,851
Awards vest expensed year one percentage	50.00%
Awards vest expensed year two percentage	25.00%
Awards vest expensed year three percentage	25.00%
Total compensation cost related to non-vested options not yet recognized, Period	3 years
Restricted Stock Units [Member] | Executives, Board of Directors and Employees [Member]
Stockholders Equity Additional (Textual)
Shares vested	418,295
2010 Stock Incentive Plan [Member]
Stockholders Equity Additional (Textual)
Share-based compensation number of shares authorized			3,750,000
Share-based compensation number of shares outstanding	2,643,523		1,540,739
Contractual life of options granted	7 years
Stock incentive plan, terms	Share limit as one (1) share for each share of common stock and any award that is a full-value award will be counted against the share limit as 1.5 shares for each one share of common stock
Shares reserved and available for issuance under the purchase plan	5,240,202
2005 Non-Employee Directors' Stock Option Plan [Member]
Stockholders Equity Additional (Textual)
Shares reserved and available for issuance under the purchase plan	125,000
Initial option to purchase common stock received by Non-employee director	6,250
Option to purchase common stock by Non-employee first elected director	6,250
Annual option to purchase common stock received by Non-employee director	10,000
2005 Employee Stock Purchase Plan
Stockholders Equity Additional (Textual)
Contribution by eligible employees under purchase plan	15.00%
Description of purchase price	Lower of: 85% of the fair market value per share on the start date of the offering period in which the employee is enrolled or 85% of the fair market value per share on the semi-annual purchase date
Compensation cost in connection with the purchase plan	4	$5
Shares reserved and available for issuance under the purchase plan	500,000
Provision for share replenishment	Lesser of 1% of the total number of shares outstanding on that date or 25,000 shares.
Share issued under purchase plan	116,263	108,074
Number of shares available for grant	383,737	366,926

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details)	12 Months Ended
	Sep. 30, 2014
Employee Benefit Plan (Textual)
Maximum annual contribution per employee, Percentage	100.00%

Subsequent_Event_Details

Subsequent Event (Details) (USD $)	12 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Nov. 11, 2014	Sep. 30, 2014
Subsequent Events (Textual)
Restricted stock units
Accrued and expensed			$197
Subsequent Event [Member] | CEO [Member]
Subsequent Events (Textual)
Closing sale price of common stock		$1.50
Restricted stock units vest		The restricted stock units vest in full on September 30, 2015